Careers  |  Sign In  |  Register

Latest in Oncology

Reuters Health • The Doctor's Channel Daily Newscast

Alkylating Agents for Hodgkin Lymphoma Tied to Risk of Secondary Leukemia

NEW YORK (Reuters Health) – Reducing exposure to alkylating agents in patients with Hodgkin lymphoma is key to reducing the risk of developing therapy-related acute myeloid leukemia or myelodysplastic syndrome (t-AML/MDS), reports a group from Stanford University, California. The finding emerged from an...
Results of a new study in The Journal of Biological Chemistry show promise for use of gedunin, an extract from an Indian tree, for cancer treatment. Inhibition of Hsp90 is a target for cancer treatment that has been less effective than expected due to “Binding of the co-chaperone p23 to Hsp90, and induced...
A new study in Cancer Research attempts to determine a new target for treatment of aggressive breast cancer tumors. Transcription factor FOXC2 “is a critical determinant of mesenchymal and stem cell properties, in cells induced to undergo EMT [epithelial-mesenchymal transition] and CSC [Cancer Stem Cell]...